Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) will announce its earnings results after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of C($0.20) per share for the quarter.
Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) last posted its quarterly earnings results on Tuesday, May 14th. The company reported C($0.21) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of C($0.21). The firm had revenue of C$0.04 million for the quarter, compared to analyst estimates of C$0.07 million.
Shares of TSE AUP traded up C$0.05 during trading hours on Monday, hitting C$8.43. 24,500 shares of the stock were exchanged, compared to its average volume of 58,344. The company has a current ratio of 23.31, a quick ratio of 22.28 and a debt-to-equity ratio of 0.30. The firm has a market cap of $773.82 million and a P/E ratio of -11.91. The firm has a fifty day moving average of C$8.32. Aurinia Pharmaceuticals has a 1-year low of C$6.61 and a 1-year high of C$10.47.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Further Reading: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.